Expression Alternations of CCR5 in New Case and Treated Patients with Multiple Sclerosis

Multiple sclerosis (MS) is a multifactorial autoimmune disease which is characterized by CNC inflammation, demyelination and various degrees of axonal damages, disrupting the communication ability of nervous system. Numerous genes are interfering with MS. Studies indicate that CC chemokine and their receptors including CCR5 play a notable role in MS procedure. Particular domain of medicines is used to cure MS which is considered as an attempt to reduce attacks and improve function after an attack. Interferon is one of 194 Shima Bayat et al. them which are believed to fulfill biological activities by some specific receptors on the cells surface. However, their mechanism still remains unknown and this would make trouble predicting the final results of the treatment. We studied the expression of CCR5 in 30 cases of MS patients which were not on any kind of drug treatment with an age of onset at 20 to 61 years old. 25 patients were on drug treatment and 25 as healthy subjects with a similar sex, age, race, physiological statues, life style situation and education matched to patients along with applying Quantitative RT-PCR. A remarkable CCR5 low-expression has observed in MS groups in comparison with healthy subjects (p<0.05). Moreover, a significant CCR5 over-expression has perceived in sedated patients comparing to the healthy group (p<0.05). Results demonstrated that CCR5 chemokine receptor could be considered as a determining receptor interacting with interferon owing to the fact that CCR5 chemokine existing in the patients’ peripheral blood who has received interferon was undeniable comparing to the others and this result could be a depiction of an effective interaction with chemokine CCR5 receptors.